FOLLOW US

In a high-stakes move poised to reshape the medical malpractice insurance industry, physician-owned insurer The Doctors Company has struck a definitive agreement to acquire ProAssurance Corp. in a colossal $1.3 billion deal. The transaction, expected to close in the first half of 2026, will forge a powerhouse with approximately $12 billion in assets.

The Legal Titans Behind the Deal

Global legal heavyweights are at the helm of this high-profile transaction. Mayer Brown LLP is steering The Doctors Company, while Simpson Thacher & Bartlett LLP and Willkie Farr & Gallagher LLP are representing ProAssurance. The sheer legal muscle involved underscores the magnitude of this merger.

A Premium Payout for Shareholders

Under the terms of the agreement, ProAssurance stockholders will receive $25 per share in cash—an eye-catching 60% premium over the company’s closing price on March 18. This premium valuation signals strong confidence in the strategic vision behind the acquisition.

The Future of ProAssurance

Upon completion, ProAssurance will become a wholly owned subsidiary of The Doctors Company and exit the New York Stock Exchange, marking the end of its publicly traded era. This bold transition aligns with a broader trend of consolidation in the insurance sector, as companies seek to fortify their positions in a rapidly evolving healthcare landscape.

A Mission-Driven Expansion

Dr. Richard E. Anderson, chair and CEO of The Doctors Company, framed the acquisition as a critical step in fulfilling the company’s mission.

He emphasized the necessity of scale in an industry undergoing seismic shifts.

Addressing a Changing Healthcare Environment

This acquisition comes as medical liability insurers navigate mounting regulatory pressures, evolving risk management challenges, and shifting healthcare delivery models. By joining forces, The Doctors Company and ProAssurance position themselves to better serve healthcare professionals across multiple specialties and regions.

Rand also highlighted the financial upside for ProAssurance shareholders, labeling the deal a significant value driver.

The Road to Completion

The deal is subject to customary closing conditions, including approval by ProAssurance stockholders and regulatory clearance. As the clock ticks toward the anticipated closing date, the industry will be watching closely to see how this merger reshapes the competitive landscape.

The Power Players Behind the Scenes

Financial advisory firms are playing a pivotal role in orchestrating this deal. Houlihan Lokey Capital and Howden Capital Markets & Advisory are advising The Doctors Company, while Goldman Sachs & Co. is providing financial counsel to ProAssurance.